Biocardia, Inc. key statistics and ratios
In fiscal 2024, Biocardia, Inc. had an operating margin of -13794.8%, debt equal to 0.0% of equity and a current ratio of 1.13. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 100.0% | — | −29.5% | −44.1% | 17.3% | 49.6% | 97.2% | 100.0% | — | — | — | — |
| Operating margin | — | <−999% | −598.3% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −880.3% | <−999% | <−999% | — |
| Net margin | — | >999% | −740.8% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −880.7% | <−999% | <−999% | — |
| Free-cash-flow margin | — | <−999% | −790.7% | — | <−999% | <−999% | <−999% | <−999% | <−999% | −786.3% | <−999% | <−999% | — |
| Return on equity | — | 118.9% | −140.5% | −120.3% | −77.6% | −187.5% | — | −139.3% | −85.4% | −156.0% | — | — | — |
| Return on assets | −211.8% | 100.8% | −72.0% | −76.5% | −69.1% | −140.2% | −208.7% | −96.5% | −64.5% | −93.3% | −181.1% | −236.8% | −230.6% |
| Asset turnover | — | 0.00 | 0.10 | 0.04 | 0.03 | 0.06 | 0.10 | 0.01 | 0.05 | 0.11 | 0.07 | 0.02 | — |
| Current ratio | — | — | 0.56 | 15.18 | 5.71 | 2.44 | 1.59 | 5.33 | 3.63 | 2.19 | 0.40 | 1.13 | 1.12 |
| Debt to equity | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% | — | 0.0% | 0.0% |
| Interest cover (operating income ÷ interest) | — | — | n/m | n/m | — | — | n/m | n/m | — | — | — | — | — |
| Effective tax rate | — | — | 0.0% | — | — | — | — | — | — | — | — | — | — |
| R&D as % of revenue | — | — | 167.9% | 578.1% | >999% | >999% | >999% | >999% | 843.2% | 653.4% | >999% | >999% | — |
| SG&A as % of revenue | — | — | 413.1% | 713.2% | >999% | 921.1% | 845.5% | >999% | 501.2% | 326.8% | 921.4% | >999% | — |
| Capital spending as % of revenue | — | >999% | 13.8% | — | 28.4% | 10.6% | 20.6% | 22.1% | 11.4% | 5.2% | 2.5% | 10.3% | — |
| Free cash flow ÷ net income | — | −33.4% | — | — | — | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q1Mar 2024 | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | <−999% | — | — | — | — | — | — |
| Net margin | <−999% | <−999% | — | — | — | — | — | — |
| Free-cash-flow margin | <−999% | <−999% | — | — | — | — | — | — |
| Current ratio | 0.31 | 0.39 | 1.78 | 1.13 | 0.36 | 0.33 | 1.62 | 1.12 |
| R&D as % of revenue | >999% | >999% | — | — | — | — | — | — |
| SG&A as % of revenue | >999% | >999% | — | — | — | — | — | — |
Moat
Weak moat
How hard Biocardia's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -163.9% of total assets over 10 years.
- Pricing power 9 / 20
Gross margin has been a median 49.6%, moving by 53.8 percentage points (standard deviation) across 5 years.
- Durability 10 / 20
Operating margin has been a median -2327.4%; its worst year was -281733.3%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 9 years, at a median -1889.1% of revenue.
- Discipline 10 / 20
The diluted share count fell 99.1% over five years; stock-based pay has been a median 355.3% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (29 before it).
More: Biotechnology stocks compared, Health Care sector, rankings of US companies